Skip to content

Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators

Post-traumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators: A Cost-effectiveness and Efficacy Comparison of Treatment as Usual and a Novel Intervention

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03152175
Enrollment
64
Registered
2017-05-12
Start date
2017-03-30
Completion date
2023-03-31
Last updated
2021-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Stress Disorder, Adjustment Disorders, Post-traumatic Stress Disorders, Trauma and Stressor Related Disorders

Keywords

Memory Reconsolidation, Propranolol, Police officers, 911 operators, Efficacy, Cost-effectiveness

Brief summary

Police officers, correctional service officers, and 911-operators are at increased risk for suffering from trauma-related disorders due to their direct and indirect exposure to life-threatening events, such as shootings, violent assaults, or car accidents, among others. Typical treatments for post-traumatic stress disorders include psychotherapy and pharmacological therapies (i.e., antidepressants). Although these interventions are effective for many sufferers, they all have limitations. Thus, the investigators propose to explore the usefulness of a new therapeutic technique, reconsolidation blockade, which involves reactivating the trauma memory while under the influence of propranolol. Objectives and hypotheses: To explore the efficacy and cost-effectiveness of reconsolidation blockade therapy as an adjunct treatment for trauma- and stressor-related disorders as defined in the Diagnostic and Statistical Manual Mental Disorders-5. The investigators hypothesize that, compared to the control group, 5 weekly trauma-memory reactivations under propranolol treatment will confer a significant reduction in trauma-related symptoms and significantly more health-related economic benefits. Stress symptoms and health-related costs will be assessed at 7, 26 and 52 weeks after study inclusion. In this study, the investigators will also explore the effects of reconsolidation blockade with propranolol on various neuropsychological functions.

Interventions

DRUGPropranolol Hydrochloride

1mg / kg of propranolol hydrochloride, oral capsule

DRUGPlacebo

1mg / kg of matched placebo, oral capsule

Sponsors

Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail
CollaboratorOTHER
Douglas Mental Health University Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Repeated measures parallel design.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Understands and reads French * Currently or previously worked for the Quebec City Police Department, or the 911 dispatch for Quebec City, or another police department or 911 dispatch in the province of Quebec, or for the Quebec Ministry of Public Security as a correctional service officer * Meets criteria for a trauma-and stressor-related disorder, such as: Acute Stress Disorder, Posttraumatic Stress Disorder, Adjustment Disorder, Other Trauma- and Stressor-Related Disorder, as defined by the Diagnostic and Statistical Manual for Mental Disorders, 5th edition. * The trauma-and stressor-related disorder must be due to a work-related event. * A score of at least 4 (moderately ill) on the Clinical Global Impressions-Severity Scale. * Participants who are currently taking a Selective Serotonin Reuptake Inhibitors or Selective Norepinephrine Reuptake Inhibitors (antidepressants) must accept to skip their morning dose on the days that they receive the study's intervention.

Exclusion criteria

* Systolic blood pressure \< 100mm Hg (millimeter of mercury) at visit 0. * Heart rate \< 55 bpm (beats per minute) at visit 0. * Medical conditions that contraindicate propranolol administration, as determined by the treating physician. * Previous diagnosis of a traumatic brain injury (TBI). * Previous adverse reaction or non-compliance with a beta-blocker. * Medications that can have an dangerous interaction with propranolol. * Fertile women who are not using an adequate contraceptive methods. * Pregnant women. * Nursing women. * The following psychiatric conditions: past or present bipolar disorder, past or present psychotic disorder, present substance abuse or dependence, actively suicidal, past or present neurological disorder, complex posttraumatic stress disorder.

Design outcomes

Primary

MeasureTime frameDescription
EuroQol five dimensions questionnaire with five-level scaleThe weighted average of the questionnaire responses will be calculated over a 12 month periodThis questionnaire is a standardized instrument for measuring generic health status

Secondary

MeasureTime frameDescription
Post-traumatic Checklist for the Diagnostic and Statistical Manual for Mental Disorders - 5th edition (PCL-5)Change from baseline (week 0) to weeks 1, 2, 3, 4 , 5, 7, 26, and 52.Measure of trauma and stressor related symptoms
Hopkins Symptom Checklist - 25 (HSCL - 25).Change from baseline (week 0) to weeks 1, 2, 3, 4 , 5, 7, 26, and 52.Measure of depression and anxiety symptom severity
Operational Police Stress Questionnaire (PSQ-OP)Change from baseline (week 0) to weeks 7, 26, and 52.Measure of severity of occupational stress

Other

MeasureTime frameDescription
Color-Word Interference Test of the Delis-Kaplan Executive Function SystemChange from baseline (week 0) to weeks 7 and 52.Measure of selective attention
Coding subtest of the Wechsler Adult Intelligence Scale-IVChange from baseline (week 0) to weeks 7 and 52.Measure of working memory
Attention subtest of the Paced Auditory Serial Addition Test (PASAT)Change from baseline (week 0) to weeks 7 and 52.Measure of working memory, divided attention, and information processing speed
Social Functioning Questionnaire (SFQ)Change from baseline (week 0) to weeks 7, 26, and 52.Measure of psycho-social functional
Verbal Fluency TestChange from baseline (week 0) to weeks 7 and 52.Measure of verbal ability and executive control
Subjective Units of Distress ScaleChanges from week 1 to weeks 2, 3, 4 and 5.Measure of subjective distress from exposure to an event
D2 Test of attentionChange from baseline (week 0) to weeks 7 and 52.Measure of selective and sustained attention
Rey's 15-Item Memory testChange from baseline (week 0) to weeks 7 and 52.Measure of verbal learning and memory
The Logical Memory subtest of the Wechsler Memory Scale - IIIChange from baseline (week 0) to weeks 7 and 52.Measure of verbal learning and memory
Trail Making TestChange from baseline (week 0) to weeks 7 and 52.Measure of mental flexibility

Countries

Canada

Contacts

Primary ContactAlain Brunet, PhD.
alain.brunet@mcgill.ca514-761-6131
Backup ContactDaniel Saumier, PhD.
irsst.brunet@gmail.com514-761-6131

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026